



Avillion Appoints Kathryn J. Gregory as Chief Business Officer

London, UK, October 3, 2017 – Avillion LLP, a drug development company focused on the co-development and financing of late-stage pharmaceutical candidates, from post proof-of-concept Phase 2 and Phase 3 to market approval, announces that it has appointed Kathryn J. Gregory, MBA, as Chief Business Officer (CBO). Ms Gregory will be based in the US and will be focused on expanding the clinical co-development opportunities for Avillion.

Ms Gregory has over 25 years of executive leadership experience in biotechnology and pharmaceutical industries. She has extensive experience in international business development including corporate strategy, negotiation, mergers & acquisitions, and operational experience in marketing, strategic sourcing and procurement.

Ms Gregory joins Avillion from Seneb BioSciences, an early-stage, rare disease company. During her career, Ms Gregory has worked in senior roles in pharmaceutical and biotechnology companies including Purdue Pharma where she was responsible for business development transactions, identification, evaluation and negotiation of new business development opportunities and collaborations. Prior to Purdue, Ms Gregory was at Shire Pharmaceuticals and was responsible for business development transactions for the Neuroscience and Ophthalmology Business Units. Earlier in her career, Ms Gregory was Vice President, Business Development for PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company, and was Head of North America Sourcing and Procurement at Teva Pharmaceuticals.

Dr Allison Jaynes-Ellis, CEO of Avillion, said: “We are delighted that Kathryn has joined Avillion as CBO, which will allow us to expand our partnerships globally and increase our presence in the US. She brings tremendous international business development and transaction experience to Avillion and complements our experienced team.”

Ms Gregory received an MBA from Pepperdine University and a BA degree from the University of California, Berkeley.

A photograph of Ms Gregory is available on request.

ENDS

About Avillion

Avillion LLP is a drug development company with an innovative business model focusing on the clinical co-development and regulatory approval of late stage pharmaceutical products. Avillion offers a compelling opportunity to partner late-stage therapeutic projects for approval in the US and EU and to accelerate their availability to the market. Our objective is to enable our partners to continue to develop the drug candidates in their pipeline at the highest quality without increasing the burden on their P&L or cash reserves. Avillion can achieve this by incurring 100% of the clinical and regulatory risk, while advancing the development of these late-stage assets in return for milestone and royalty payments on the commercialisation of successfully developed products.

To date, Avillion has advanced Pfizer’s BOSULIF® (bosutinib) successfully through Phase 3 trials into registration aiming to expand its approved use to include patients with newly diagnosed chronic phase



Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia. Avillion is also undertaking Phase 2 trials with Merck's anti IL-17 A/F Nanobody® in plaque psoriasis.

Avillion was founded in 2012 in London, UK, and is backed by Abingworth, Clarus Ventures and Royalty Pharma.

www.avillionllp.com

Contacts

Allison Jaynes-Ellis, CEO
Tel: +44 (0)203 764 9531
Email: allison@avillionllp.com

Mark Swallow, Citigate Dewe Rogerson
Tel: +44 (0)207 282 2948
Email: mark.swallow@citigatedr.co.uk